Related Experiment Videos
Adalimumab for treating rheumatoid arthritis.
Federico Navarro-Sarabia1, Rafael Ariza-Ariza, Blanca Hernández-Cruz
1Rheumatology Service, Hospital Universitario Virgen Macarena, Sevilla, Spain.
The Journal of Rheumatology
|May 3, 2006
Summary
Adalimumab effectively treats rheumatoid arthritis (RA), improving patient responses and slowing disease progression. This review found no serious adverse effects associated with its use in RA patients.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and potential for progressive joint damage.
- Adalimumab, a biologic disease-modifying antirheumatic drug (bDMARD), targets tumor necrosis factor-alpha (TNF-α) and is used in RA treatment.
Purpose of the Study:
- To systematically review and synthesize evidence on the efficacy and safety of adalimumab for treating rheumatoid arthritis.
- To evaluate adalimumab's impact on clinical response, disease activity, and radiographic progression in RA patients.
Main Methods:
- A Cochrane systematic review methodology was employed, including literature search, study selection, quality assessment, and data extraction.
- Outcome measures included American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) response criteria, Disease Activity Score 28 (DAS28), and radiographic changes.
- Data analysis involved calculating weighted mean differences and relative risks, with number needed to treat (NNT) and number needed to harm (NNH) estimated where appropriate.
Main Results:
- Six studies involving 2,390 patients demonstrated adalimumab's efficacy. Adalimumab 40 mg every other week (eow) plus methotrexate showed significant improvements in ACR20, ACR50, and ACR70 responses at 52 weeks (NNTs 2.9, 3.1, 5.3).
- Adalimumab (40 mg eow and 20 mg every week) significantly slowed radiological progression at 52 weeks.
- Compared to placebo, adalimumab 40 mg eow resulted in higher ACR20, ACR50, and ACR70 responses at 24/26 weeks (NNTs 5.0, 7.0, 9.0).
Conclusions:
- Adalimumab is an efficacious treatment for rheumatoid arthritis, demonstrating significant improvements in clinical outcomes.
- The reviewed studies indicated no significant differences in safety outcomes between adalimumab and control groups, with no serious adverse effects reported.